Publications

486 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

GVS advice icosapent-ethyl (Vazkepa®)

The National Health Care Institute has completed its assessment whether the product icosapent-ethyl (Vazkepa®) can be included in ...

Report | 15-02-2023
Package advice on the lock procedure medicinal product tafasitamab (Minjuvi®) for the treatment of lymphoma

The National Health Care Institute has assessed whether the medicinal product tafasitamab (Minjuvi®) can be reimbursed from the ...

Report | 15-02-2023
GVS advice patiromer (Veltassa®) cancellation List 2 conditions

The Minister of Health, Welfare and Sport (VWS) has adopted the recommendation of the National Health Care Institute. This means ...

Report | 01-02-2023
GVS advice empagliflozin (Jardiance®) extension List 2 conditions

At the request of the Minister of Health, Welfare and Sport (VWS), The National Health Care Institute will assess whether the ...

Report | 31-01-2023
GVS advice dexamethasone/levofloxacin eye drops (Ducressa®) for use by adults after cataract surgery

The National Health Care Institute has assessed whether dexamethasone/levofloxacin (Ducressa®) can be included in the Medicine ...

Report | 25-01-2023
GVS advice PCV15 (Vaxneuvance®) to prevent severe progression of pneumococcal disease in people in medical high-risk groups

The National Health Care Institute has assessed whether the 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15, ...

Report | 25-01-2023
GVS advice odevixibat (Bylvay®) for the treatment of progressive familial intrahepatic cholestasis

The National Health Care Institute has assessed whether odevixibat (Bylvay®) can be included in the Medicine Reimbursement System ...

Report | 18-01-2023
GVS advice solriamfetol (Sunosi®) for the treatment of narcolepsy or obstructive sleep apnoea

The National Health Care Institute has completed its assessment whether the medicinal product solriamfetol (Sunosi®) can be ...

Report | 23-12-2022
Appendix to guideline for cost-effectiveness models in R - packages and versions

Appendix to guideline for cost-effectiveness models in R - packages and versions.

Publication | 15-12-2022
Guideline for building cost-effectiveness models in R

Guideline for building cost-effectiveness models in R.

Publication | 15-12-2022

Publications

486 publications

GVS advice icosapent-ethyl (Vazkepa®)

Package advice on the lock procedure medicinal product tafasitamab (Minjuvi®) for the treatment of lymphoma

GVS advice patiromer (Veltassa®) cancellation List 2 conditions

GVS advice empagliflozin (Jardiance®) extension List 2 conditions

GVS advice dexamethasone/levofloxacin eye drops (Ducressa®) for use by adults after cataract surgery

GVS advice PCV15 (Vaxneuvance®) to prevent severe progression of pneumococcal disease in people in medical high-risk groups

GVS advice odevixibat (Bylvay®) for the treatment of progressive familial intrahepatic cholestasis

GVS advice solriamfetol (Sunosi®) for the treatment of narcolepsy or obstructive sleep apnoea

Appendix to guideline for cost-effectiveness models in R - packages and versions

Guideline for building cost-effectiveness models in R

Go to